Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: eHealth interventions are widely used in clinical trials and increasingly in care settings as well; however, their efficacy in real-world contexts remains unknown. ReMindCare is a smartphone app that has been systematically implemented in a first episode of psychosis program (FEPP) for patients with early psychosis since 2018.
Objective: The objective of this study was to assess the efficacy of ReMindCare after 19 months of use in the clinic and varying use by individual patients.
Methods: The integration of the ReMindCare app into the FEPP started in October 2018. Patients with early psychosis self-selected to the app (ReMindCare group) or treatment as usual (TAU group). The outcome variables considered were adherence to the intervention and number of relapses, hospital admissions, and visits to urgent care units. Data from 90 patients with early psychosis were analyzed: 59 in the ReMindCare group and 31 in the TAU group. The mean age of the sample was 32.8 (SD 9.4) years, 73% (66/90) were males, 91% (83/90) were White, and 81% (74/90) were single.
Results: Significant differences between the ReMindCare and TAU groups were found in the number of relapses, hospitalizations, and visits to urgent care units, with each showing benefits for the app. Only 20% (12/59) of patients from the ReMindCare group had a relapse, while 58% (18/31) of the TAU patients had one or more relapses (χ=13.7, P=.001). Moreover, ReMindCare patients had fewer visits to urgent care units (χ=7.4, P=.006) and fewer hospitalizations than TAU patients (χ=4.6, P=.03). The mean of days using the app was 352.2 (SD 191.2; min/max: 18-594), and the mean of engagement was 84.5 (SD 16.04).
Conclusions: To our knowledge, this is the first eHealth intervention that has preliminarily proven its benefits in the real-world treatment of patients with early psychosis.
International Registered Report Identifier (irrid): RR2-10.1111/eip.12960.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679204 | PMC |
| http://dx.doi.org/10.2196/22997 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Case Series of Young People Receiving Adjunctive Immunotherapy for Neuroimmune-Mediated Major Mood or Psychotic Syndromes.
Biol Psychiatry Glob Open Sci
November 2025
Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.
Background: Neuroimmune processes are often implicated in young people with atypical neuropsychiatric disorders, yet treatment implications remain controversial. This case series details young people with primary psychiatric disorders who received adjunctive immunotherapy after thorough investigation and extensive conventional treatments.
Methods: We evaluated 45 individuals (93% female, ages 12-30 years) with atypical psychiatric presentations suggesting potential neuroimmune involvement.
A Multimodal Observational Case-Control Study Exploring Gut Microbiota-Hippocampus Alterations in Individuals With High Positive Schizotypy From the General Population.
Biol Psychiatry Glob Open Sci
November 2025
University of Basel, Department of Clinical Research (DKF), University Psychiatric Clinics, Translational Neurosciences, Basel, Switzerland.
Background: The hippocampus plays a critical role in psychosis, with reduced volume observed across the psychosis continuum. These structural changes are associated with cognitive deficits, symptom severity, and increased risk of psychosis progression. Elevated hippocampal perfusion and glutamate/GABA (gamma-aminobutyric acid) imbalance further suggest metabolic dysregulation as a key mechanism.
View Article and Find Full Text PDFUnveiling Psychiatric Manifestations in a Case of Moyamoya Disease.
Cureus
August 2025
Psychiatry, Rashid Hospital, Dubai Health, Dubai, ARE.
Moyamoya disease (MMD) is a rare and progressive cerebrovascular disorder characterized by stenosis of the internal carotid arteries and their major branches, leading to the development of abnormal collateral vessels. While MMD is traditionally associated with ischemic and hemorrhagic strokes, there is increasing recognition of the psychiatric symptoms that can accompany the disease, which significantly impact patient outcomes and complicate management. This case report presents a 30-year-old female with a history of recurrent ischemic strokes, hypertension, diabetes, and dyslipidemia, who initially presented with neurological symptoms including headache, left-sided weakness, and facial deviation.
View Article and Find Full Text PDFDopamine DR availability after discontinuation of antipsychotic treatment: a [C]raclopride PET study in remitted first-episode psychosis patients.
Psychol Med
September 2025
https://ror.org/03cv38k47University of Groningen, University Medical Centre Groningen, Center for Clinical Neuroscience and Cognition, Groningen, The Netherlands.
Background: After remission of a first-episode psychosis (FEP), antipsychotic discontinuation is associated with an increased risk of relapse compared to maintenance treatment. We studied short and longer-term effects of discontinuation of D receptor (DR) antagonist and partial agonist antipsychotics on striatal dopamine DR availability in FEP patients.
Methods: Remitted FEP patients underwent two [C]raclopride PET scans to measure striatal DR availability: 1 week after antipsychotic discontinuation (n = 16 antagonist users, n = 6 partial agonist users) and after being medication free for 6-8 weeks (n = 8 antagonist users, n = 5 partial agonist users).
Diagnostic and transition accuracy of natural language processing in high risk for psychosis individuals: A systematic review.
Asian J Psychiatr
September 2025
Department of Psychiatry and Mental Health, Faculty of Medicine, Universidad de Chile, Santiago, Chile; Translational Psychiatry Laboratory (Psiquislab), Faculty of Medicine, Universidad de Chile, Santiago, Chile; Millennium Nucleus to Improve the Mental Health of Adolescents and Youths (IMHAY), San
Background: Schizophrenia spectrum disorders often emerge in adolescence or early adulthood and are a leading cause of global disability. Early identification of clinical high‑risk for psychosis (CHR‑P) can reduce comorbidity and shorten untreated psychosis duration, yet clinician‑administered tools (e.g.
View Article and Find Full Text PDF